SYK · XBRL financial data

Stryker financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SYK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	14,351	17,108	18,449	20,498	22,595	25,116
Cost of revenue	5,294	6,140	6,871	7,440	8,155	9,051
Gross profit	9,057	10,968	11,578	13,058	14,440	16,065
Research and development	984	1,235	1,454	1,388	1,466	1,623
Selling, general and administrative	5,361	6,427	6,455	7,129	7,685	8,651
Total operating expenses	6,834	8,384	8,737	9,170	10,751	11,176
Operating income (loss)	2,223	2,584	2,841	3,888	3,689	4,889
Interest expense	315	337	337	363	409	607
Income tax expense (benefit)	355	287	325	508	499	1,268
Net income (loss)	1,599	1,994	2,358	3,165	2,993	3,246
Earnings per share, basic USD per share	4.26	5.29	6.23	8.34	7.86	8.49
Earnings per share, diluted USD per share	4.20	5.21	6.17	8.25	7.76	8.40
Weighted average shares, basic millions of shares	376	377	378	380	381	382
Weighted average shares, diluted millions of shares	380	382	382	384	386	387

Fiscal years (SYK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,943	2,944	1,844	2,971	3,652	4,011
Marketable securities	81	75	84	82	91	89
Accounts receivable	2,701	3,022	3,565	3,765	3,987	4,039
Inventory	3,494	3,314	3,995	4,843	4,774	5,310
Total current assets	9,707	10,017	10,275	12,518	14,847	14,755
Property and equipment, net	2,752	2,833	2,970	3,215	3,448	3,876
Right-of-use asset	423	419	473	494	516	519
Goodwill	12,778	12,918	14,880	15,243	15,855	19,291
Total assets	34,330	34,631	36,884	39,912	42,971	47,844
Commercial paper	0	0	0	0	0	0
Total current liabilities	5,041	4,549	6,303	7,921	7,616	7,794
Long-term debt	13,230	12,472	11,857	10,901	12,188	14,859
Lease liability, non-current	325	310	357	356	379	348
Total liabilities	21,246	19,754	20,268	21,319	22,337	25,424
Retained earnings	12,462	13,480	14,765	16,771	18,528	20,472
Total liabilities and equity	34,330	34,631	36,884	39,912	42,971	47,844
Common shares outstanding (cover page) millions of shares	376	378	379	380	382	383

Fiscal years (SYK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,599	1,994	2,358	3,165	2,993	3,246
Stock-based compensation	142	171	168	205	229	243
Depreciation and amortization	1,076	1,272	1,278	1,341	1,426	1,570
Net cash from operating activities	3,277	3,263	2,624	3,711	4,242	5,044
Purchases of property and equipment	487	525	588	575	755	761
Net cash from investing activities	(4,701)	(859)	(2,924)	(962)	(3,000)	(4,866)
Share repurchases	0	0	—	—	—	—
Dividends paid	863	950	1,051	1,139	1,219	1,284
Proceeds from long-term debt	3,292	5	1,500	1,241	3,011	2,979
Repayments of long-term debt	2,297	1,151	653	2,058	2,039	1,400
Net cash from financing activities	(11)	(2,365)	(749)	(1,594)	(525)	113
Net change in cash	(1,394)	1	(1,100)	1,127	681	359

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Stryker	3,271	6,520	1,461*	380.7M	Q3 FY26 10-QSep 30, 2026
Boston Scientific	609	5,138	1,048*	1.4B	Q3 FY26 10-QSep 30, 2026
Medtronic	1,691	9,756	1,793	1.3B	Q1 FY27 10-QJul 31, 2026
Intuitive Surgical	2,978	3,049	1,224*	346.6M	Q3 FY26 10-QSep 30, 2026
3M	4,835	6,584	486*	516.7M	Q3 FY26 10-QSep 30, 2026
Becton Dickinson	708	4,983	not reported	272.4M	Q3 FY26 10-QJun 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	Q2 FY26 10-QJun 30, 2026
Resmed	1,011	1,415	422	140.7M	Q1 FY27 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.